Loading AI feed…
Vaxcyte
Action, confidence, horizon, and decision blockers at a glance.
Fast scan of bull, bear, and watch items
High-level snapshot
Thesis highlights from the latest analysis
Scannable catalysts and supporting factors
Other notable items detected
Next few weeks
Months to a year
| Symbol | Summary |
|---|---|
| MRK | Merck is the clearest direct operating comparator because VAX-31 is being positioned against CAPVAXIVE in adult pneumococcal vaccination, making competitive immunogenicity, serotype breadth and safety central to any eventual commercial case. [#10-K-2026-02-24] |
| PFE | Pfizer is the other direct operating comparator because OPUS-1 is designed against Prevnar 20, so a positive readout still has to translate into credible differentiation versus the incumbent adult PCV benchmark. [#10-K-2026-02-24] |
| NUVL | Nuvalent is only a public-market valuation and maturity reference for a well-capitalized, pre-revenue clinical biotech; it is not a direct vaccine or pneumococcal competitor, so it should not carry much weight in the operating peer frame. |
Internal and external references used in this analysis